Updates in the Management of Mantle Cell Lymphoma: Is There Still a Role for Transplant?
Recent advances in mantle cell lymphoma represent a major paradigm shift. Educating the clinicians about the recent advances and the benefits/risks associated with the use of hematopoietic cell transplant, BTK inhibitors (BTKi) and CAR T-cell therapy can help them make informed clinical decisions for individual patients.
Category
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Perioperative Management of Anticoagulation and Antithrombotic Therapy
Perioperative management of anticoagulation and antithrombotic therapy is challenging, and accurate knowledge and assessment of thromboembolic and bleeding risks will aid providers in making appropriate decisions regarding holding of anticoagulation, bridging anticoagulation, and post-procedural resumption of anticoagulation.
Category
- Venous Thromboembolic Disease
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
There is a continuing need to educate clinicians about the emerging treatment options as this will aid in the successful implementation of more effective treatment options in routine clinical setting.
Category
- Chronic Lymphocytic Leukemia
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies
Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.
Category
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
There is a continuing need to educate clinicians about the differences in toxicity profiles between TKIs and the various strategies that are being evaluated in clinical trials to mitigate the risk of adverse events associated with TKI therapy for CML and MPN.
Category
- Chronic Myelogenous Leukemia
- Myeloproliferative Neoplasms
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Bone Disease Management and Infections in Multiple Myeloma
With improvement in treatment options and supportive care, patients with multiple myeloma (MM) are living longer. The majority of patients with MM are at risk for osteolytic bone lesions, osteoporosis, and infections among other complications. The outcomes of patients with MM can be improved by effective management of infections; recognizing and managing side effects of bone modifying therapy; and implementing plans of care to promote health, safety, mobility, and overall improved quality of life.
Category
- Multiple Myeloma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Management of Lower-Risk Myelodysplastic Syndromes
The management of myelodysplastic syndromes is complicated by the generally advanced age of the patients, the non-hematologic comorbidities seen in this cohort, and the relative inability of older patients to tolerate certain intensive forms of therapy. There are limited treatment options for patients with disease progression, especially for those with disease refractory to hypomethylating agents.
Category
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Management of Graft-Versus-Host Disease in Hematopoietic Cell Transplant Recipients
GvHD is a potentially serious complication that significantly impacts quality of life in patients undergoing allogeneic HCT. Treatment of GvHD can be optimized by providing coordinated care involving a multidisciplinary team preferably in medical centers which have access to specialized GvHD clinics. Oncology practitioners require ongoing education for the optimal management of patients with GvHD.
Category
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Updates in the Management of Myelofibrosis
As data on novel therapies emerge, it is essential that clinicians are aware of recent developments so they can best evaluate the needs of the patients and select an optimal therapeutic strategy with the goal of improving clinical outcomes.
Category
- Myeloproliferative Neoplasms
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Management of Waldenström Macroglobulinemia
The treatment armamentarium for WM/LPL continues to grow, and the selection of therapy for initial management of patients with symptomatic WM depends on age, the severity of symptoms, presence of comorbidities, and patient preferences.
Category
Format
- Recorded Webcast
Credits
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation